Results 151 to 160 of about 3,705,584 (258)

Digital and Biomarker-Based Monitoring for Schizophrenia-Treatment Adherence. [PDF]

Neuropsychopharmacol Rep
Inshutiyimana S, Rana KR, Aleu MM, Bwalya N, Nsengimana B, Kipkurui O.   +5 more
europepmc   +1 more source

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source

2-methoxyestradiol is effective in 2D and 3D models of NCI-H2170 lung squamous cell carcinoma cells. [PDF]

PLoS One
Mellor P, Kendall S, Anderson DH.
europepmc   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

Molecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic, Rafael Stroggilos, Mladen Marinkovic, Ana Djuric, Suzana Stojanovic‐Rundic, Radmila Jankovic, Sergi Castellvi‐Bel, Remond J.A. Fijneman, Antonia Vlahou, Jerome Zoidakis, Milena Cavic   +10 more
wiley   +1 more source

Human Radiolabeled Mass Balance Studies Supporting New Drugs Approved by FDA Between 2019 and 2023. [PDF]

Clin Transl Sci
Ramamoorthy A, Chen A, Chow ECY, Guinn D, Iyer A, Pahwa S, Ren Y, Shukla C, Doddapaneni S, Danielsen ZY.   +9 more
europepmc   +1 more source

Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy

Molecular Oncology, EarlyView.
We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen, Zhi Zhao, Henrik Horndalsveen, Maria Moksnes Bjaanæs, Bjørn Henning Grønberg, Tarje Halvorsen, Tesfaye Madebo, Marianne Aanerud, Jussi Koivunen, Kersti Oselin, Saulius Cicenas, Nina Helbekkmo, Jarkko Ahvonen, Maria Silvoniemi, Tine Norman Alver, Tonje Dalen, Åsa Kristina Öjlert, Saima Jamil Farooqi, Åslaug Helland, Vilde Drageset Haakensen   +19 more
wiley   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira, Ana Teixeira‐Marques, Rui Freitas, João A Carvalho, Sara Monteiro‐Reis, Giorgio I. Russo, Rui Henrique, Carmen Jerónimo   +7 more
wiley   +1 more source